HOLON, Israel, Feb. 20.
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:
CGEN) a clinical-stage cancer immunotherapy company and a pioneer
in computational target discovery, today announced that the Company
will release its fourth quarter and full year 2023 financial
results on Tuesday, March 5, 2024,
before the U.S. financial markets open. Management will host a
conference call and webcast to review the results and provide a
corporate update at 8:30 AM ET.
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S., or +972-3-918-0644
internationally. The call will be available via live webcast
through Compugen's website, located at the following link.
Following the live webcast, a replay will be available on the
Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, Compugen's therapeutic
pipeline of early-stage immuno-oncology programs consists of
programs aiming to address various mechanisms of immune resistance,
of which the most advanced program, in IND enabling studies is
COM503, which is licensed to Gilead. COM503 is a potential
first-in-class, high affinity antibody which blocks the interaction
between IL-18 binding protein and IL-18, thereby freeing natural
IL-18 in the tumor microenvironment to inhibit cancer growth.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2023-results-on-tuesday-march-5-2024-302065833.html
SOURCE Compugen Ltd.